Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532325 | 0.76 | TRPV1 (0.47) | PTGS1TRPV1PTGS2 | |
| SCHEMBL14797719 | 0.72 | TRPV1 (0.42) | PTGS1TRPV1PTGS2TKTTLR8 | |
| SCHEMBL2528526 | 0.71 | TRPV1 (0.45) | PTGS1TRPV1PTGS2 | |
| SCHEMBL2536999 | 0.71 | TRPV1 (0.45) | PTGS1TRPV1PTGS2TLR8 | |
| SCHEMBL2525752 | 0.70 | TRPV1 (0.46) | PTGS1TRPV1PTGS2 | |
| SCHEMBL2525244 | 0.69 | TRPV1 (0.46) | PTGS1TRPV1PTGS2 | |
| SCHEMBL2870247 | 0.69 | KDM4E (0.39) | TRPV1TKT | |
| SCHEMBL2526238 | 0.68 | TRPV1 (0.43) | PTGS1TRPV1PTGS2 | |
| SCHEMBL2529879 | 0.67 | TRPV1 (0.43) | TRPV1PTGS2 | |
| SCHEMBL2525510 | 0.66 | MBOAT4 (0.51) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | PTGS1 1704/4885TRPV1 1/4885PTGS2 1541/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | PTGS1 1704/4885TRPV1 1/4885PTGS2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.